1. Market Research
  2. > Preclinical Stage Partnering Terms and Agreements 2010-2015

Preclinical Stage Partnering Terms and Agreements 2010-2015

  • December 2015
  • -
  • Currentpartnering
  • -
  • 2189 pages

The Preclinical Stage Partnering Terms and Agreements 2010-2015 report provides comprehensive understanding and unprecedented access to the preclinical stage partnering deals and agreements entered into by the worlds leading healthcare companies.

Description
The Preclinical Stage Partnering Terms and Agreements 2010-2015 report provides comprehensive understanding and unprecedented access to the preclinical stage partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter preclinical stage partnering deals. The majority of deals are where the licensee obtains a right or an option right to license the licensors product or compound. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest preclinical agreements announced in the healthcare sector.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all preclinical stage partnering deals announced since 2010 including financial terms where available including over 2,000 links to online deal records of actual preclinical partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of preclinical stage deal making and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of why companies partner preclinical stage compounds/products.

Chapter 3 provides an overview of preclinical stage deals strategy and deal structure including numerous case studies. Chapter 4 provides an overview of the various payment strategies used in preclinical stage deals.

Chapter 5 provides a review of trends in preclinical stage deal making since 2010. Deals are listed by big pharma and big biotech dealmaking in preclinical stage, deal type, therapy type and technology type.

Chapter 6 provides a detailed analysis of preclinical stage payment terms including average headline, upfront, milestone and royalty rates for preclinical deals.

Chapter 7 provides a review of the leading preclinical stage deal by headline value.

Chapter 8 provides a comprehensive listing of the top 50 big pharma and top 50 big biotech companies with a brief summary followed by a comprehensive listing of preclinical stage deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 9 provides a comprehensive and detailed review of preclinical stage partnering deals signed and announced since 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 10 provides a comprehensive directory of preclinical stage partnering deals since 2010 organized by stage of development – preclinical.

The report also includes numerous tables and figures that illustrate the trends and activities in preclinical stage partnering and deal making since 2010.

In addition, a comprehensive appendix is provided organized by partnering company A-Z , deal type, therapy focus and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of preclinical stage products and compounds.

Benefits
Preclinical Stage Partnering Terms and Agreements 2010-2015 provides the reader with the following key benefits:

In-depth understanding of preclinical stage deal trends since 2010
Access to headline, upfront, milestone and royalty data
Comprehensive access to over 2,000 preclinical stage deals together with contract documents if available
Detailed access to actual preclinical stage deals entered into by the leading fifty big pharma and big biotech companies along with other biopharma companies
Analysis of the structure of preclinical stage agreements with numerous real life case studies
Identify leading preclinical stage deals by value since 2010
Identify the most active preclinical stage dealmakers since 2010
Full listing of preclinical stage deals by company A-Z, phase of development, deal type, therapy and technology focus
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table Of Contents

Preclinical Stage Partnering Terms and Agreements 2010-2015
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Why do companies partner preclinical stage compounds?

2.1. Introduction
2.2. The role of preclinical stage partnering
2.2.1. In-licensing at preclinical stage
2.2.2. Out-licensing at preclinical stage
2.3. Difference between discovery, preclinical and clinical stage deals
2.4. Reasons for entering into preclinical stage partnering deals
2.4.1. Licensors reasons for entering preclinical stage deals
2.4.2. Licensees reasons for entering preclinical stage deals
2.5. The future of preclinical stage partnering deals

Chapter 3 - Preclinical stage deal strategies and structure

3.1. Introduction
3.2. At what stage do companies partner?
3.2.1. Partnering early in pharmaceutical / biotech
3.2.1.1. Discovery and preclinical stage partnering case studies
3.2.1.1.a. Case study: LEO Pharma - 4SC
3.2.1.1.b. Case study: Heptares Therapeutics - Cubist
3.2.1.1.c. Case study: Incyte - Agenus Bio
3.2.1.1.d. Case study: Janssen Pharmaceutical - Evotec
3.2.2. Partnering later in pharmaceutical/biotech
3.2.2.1. Clinical stage partnering case studies
3.2.2.1.a. Case study: Servier - GeNeuro
3.2.2.1.b. Case study: Teva - Xenon Pharmaceuticals
3.2.2.1.c. Case study: AstraZeneca - Ardelyx
3.2.2.1.d. Case study: Baxter - Onconova Therapeutics
3.3. Early and later stage partnering - a risk/cost comparison
3.4. What do companies spend on preclinical stage partnering?
3.5. Pure versus multi-component partnering deals
3.6. Pure licensing agreement structure
3.6.1. Example pure preclinical stage licensing agreements
3.6.1.a. Case study : Merck and Co. - Tesaro
3.6.1.b. Case study : Marina Biotech - Mirna Therapeutics
3.7. Multicomponent preclinical stage partnering agreements
3.7.1. Example multicomponent preclinical stage clauses
3.7.1.a. Case study: Eleven Biotherapeutics - ThromboGenics
3.7.1.b. Case study: Pfizer - InSite Vision

Chapter 4 - Preclinical stage partnering payment strategies

4.1. Introduction
4.2. Preclinical stage payment strategies
4.3. Payment options
4.3.1. Headline values
4.3.2. Upfront payments
4.3.2.1. Conditionality of upfront payments
4.3.3. Loans
4.3.4. Convertible loans
4.3.5. Equity
4.3.6. RandD funding
4.3.7. Licensing fees
4.3.8. Milestone payments
4.3.9. Royalty payments
4.3.9.1. Issues affecting royalty rates
4.3.9.2. Royalties on combination products
4.3.9.2.a. Case study: Scripps Research Institute-Cyanotech
4.3.9.3. Guaranteed minimum/maximum annual payments
4.3.9.4. Royalty stacking
4.3.9.5. Royalties and supply/purchase contracts
4.3.10. Quids
4.3.11. Option payments

Chapter 5 - Trends in preclinical stage deal making

5.1. Introduction
5.2. Preclinical stage partnering over the years
5.2.1.. Attributes of preclinical deals
5.3. Big pharma preclinical stage dealmaking activity
5.4. Big biotech preclinical stage dealmaking activity
5.5. Preclinical stage partnering by deal type
5.6. Preclinical stage partnering by disease type
5.7. Partnering by preclinical stage technology type

Chapter 6 - Average payment terms for preclinical stage partnering

6.1. Introduction
6.2. Guidelines for preclinical stage payment terms
6.2.1. Upfront payments
6.2.2. Milestone payments
6.2.3. Royalty payments
6.3. Preclinical stage payment terms - deal data analysis
6.3.1. Public data
6.3.2. Survey data
6.4. Payment terms analysis
6.4.1. Preclinical stage headline values
6.4.1.a Graphic representation of headline value distribution 2010-2015
6.4.1.b Median headline value for preclinical stage, 2010-2015
6.4.2. Preclinical stage upfront payments
6.4.2.a Graphic representation of upfront value distribution 2010-2015
6.4.2.b Median upfront value distribution for preclinical stage, 2010-2015
6.4.3. Preclinical stage milestone payments
6.4.3.a Graphic representation of milestone value distribution 2010-2015
6.4.3.b Median milestone value distribution for preclinical stage, 2010-2015
6.4.4. Preclinical stage royalty rates
6.4.4.a Graphic representation of royalty rate distribution, 2010-2015
6.4.4.b Median royalty rate value distribution for preclinical stage, 2010-2015

Chapter 7 - Leading preclinical stage deals

7.1. Introduction
7.2. Top preclinical stage deals by value

Chapter 8 - Big pharma and big biotech preclinical stage partnering deals

8.1. Introduction
8.2. How to use big pharma/big biotech preclinical stage partnering deals
8.3. Big pharma preclinical stage partnering company profiles
8.4. Big biotech preclinical stage partnering company profiles

Chapter 9 - Preclinical stage partnering contracts directory

9.1. Introduction
9.2. Company A-Z
9.3. By deal type
9.4. By therapy area

Chapter 10 - Preclinical stage dealmaking directory

10.1. Introduction
10.2. Preclinical stage deals by year
Preclinical stage deals - 2015
Preclinical stage deals - 2014
Preclinical stage deals - 2013
Preclinical stage deals - 2012
Preclinical stage deals - 2011
Preclinical stage deals - 2010

About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from Current Partnering
Order Form - Upgrades to subscription access products
Order Form - Reports

View the accompanying volume for:

Appendices

Introduction

Appendix 1 - Directory of preclinical stage deals by company A-Z 2010-2015
Appendix 2 - Directory of preclinical stage deals by deal type 2010-2015
Appendix 3 - Directory of preclinical stage deals by therapy area 2010-2015
Appendix 4 - Partnering resource center
Online partnering
Partnering events
Further reading on dealmaking

Table of figures

Figure 1: Definition of discovery, preclinical and clinical phases in dealmaking
Figure 2: Agreements signed by phase of development (2010-2015), % of all deals
Figure 3: Components of the pure licensing deal structure
Figure 4: Payment options for preclinical stage partnering deals
Figure 5: Issues affecting royalty rates
Figure 6: Preclinical stage partnering frequency 2010-2015
Figure 7: Big pharma - top 50 - preclinical stage deals 2010 to 2015
Figure 8: Big pharma preclinical stage deal frequency - 2010 to 2015
Figure 9: Big biotech - top 50 - preclinical stage deals 2010 to 2015
Figure 10: Big biotech preclinical stage deal frequency - 2010 to 2015
Figure 11: Preclinical stage partnering by deal type since 2010
Figure 12: Preclinical stage partnering by disease type since 2010
Figure 13: Preclinical stage partnering by technology type since 2010
Figure 14: Review of upfront payments for preclinical stage deals 2010-2015
Figure 15: Review of milestone payments for preclinical stage deals 2010-2015
Figure 16: Review of royalty payments for preclinical stage deals 2010-2015
Figure 17: Preclinical stage deals with a headline value - 2010
Figure 18: Preclinical stage deals with a headline value - 2011
Figure 19: Preclinical stage deals with a headline value - 2012
Figure 20: Preclinical stage deals with a headline value - 2013
Figure 21: Preclinical stage deals with a headline value - 2014
Figure 22: Preclinical stage deals with a headline value - 2015
Figure 23: Preclinical stage deal headline value distribution, US$million
Figure 24: Summary median headline value for preclinical stage of development, 2010-2015
Figure 25: Preclinical stage deals with upfront payment values - 2010
Figure 26: Preclinical stage deals with upfront payment values - 2011
Figure 27: Preclinical stage deals with upfront payment values - 2012
Figure 28: Preclinical stage deals with upfront payment values - 2013
Figure 29: Preclinical stage deals with upfront payment values - 2014
Figure 30: Preclinical stage deals with upfront payment values - 2015
Figure 31: Preclinical stage deal upfront value distribution, US$million
Figure 32: Summary median upfront payments preclinical stage of development, 2010-2015
Figure 33: Preclinical stage deals with milestone payments - 2010
Figure 34: Preclinical stage deals with milestone payments - 2011
Figure 35: Preclinical stage deals with milestone payments - 2012
Figure 36: Preclinical stage deals with milestone payments - 2013
Figure 37: Preclinical stage deals with milestone payments - 2014
Figure 38: Preclinical stage deals with milestone payments - 2015
Figure 39: Summary median milestone payments for preclinical stage of development, 2010-2015
Figure 40: Preclinical stage deals with royalty rates, % - 2010
Figure 41: Preclinical stage deals with royalty rates, % - 2011
Figure 42: Preclinical stage deals with royalty rates, % - 2012
Figure 43: Preclinical stage deals with royalty rates, % - 2013
Figure 44: Preclinical stage deals with royalty rates, % - 2014
Figure 45: Preclinical stage deals with royalty rates, % - 2015
Figure 46: Summary median royalty rate for preclinical stage of development, 2010-2015
Figure 47: Top preclinical stage deals by value since 2010

For the full list of companies mentioned in the report, please contact enquiry@currentpartnering.com

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.